Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Elevance Health (ELV)

Elevance Health Q2 EPS rises 26% to $9.85 as revenue dips 0.4%

Mixed Impact 3 of 5 earnings Written later

Elevance Health reported second quarter 2024 results, with GAAP diluted EPS of $9.85, up 26%, and adjusted diluted EPS of $10.12, up 12%. Operating revenue slipped to $43.2 billion from $43.4 billion, while the company said it has prudently maintained its full-year outlook of at least $37.20 in adjusted EPS.

Key points

  • Q2 2024 operating revenue was $43.2 billion, down $0.2 billion from the prior year quarter, driven by Medicaid membership attrition
  • GAAP diluted EPS was $9.85 versus $7.79 a year earlier; adjusted diluted EPS was $10.12 versus $9.04
  • Full-year 2024 outlook: GAAP diluted EPS of at least $34.05 and adjusted diluted EPS of at least $37.20
  • Board declared a third quarter dividend of $1.63 per share, payable September 25, 2024, to holders of record on September 10, 2024

The filing

CompanyElevance Health (ELV)
Form8-K, current report
Filed with the SECJul 17, 2024, 6:09 AM ET
Accession number0001156039-24-000101

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 17, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.